MartÃn GarcÃa-Sancho, A.; Presa, M.; Pardo, C.; MartÃn-Escudero, V.; Oyagüez, I.; Ortiz-Maldonado, V.
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers 2024, 16, 2301.
https://doi.org/10.3390/cancers16132301
AMA Style
MartÃn GarcÃa-Sancho A, Presa M, Pardo C, MartÃn-Escudero V, Oyagüez I, Ortiz-Maldonado V.
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers. 2024; 16(13):2301.
https://doi.org/10.3390/cancers16132301
Chicago/Turabian Style
MartÃn GarcÃa-Sancho, Alejandro, MarÃa Presa, Carlos Pardo, Victoria MartÃn-Escudero, Itziar Oyagüez, and ValentÃn Ortiz-Maldonado.
2024. "Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain" Cancers 16, no. 13: 2301.
https://doi.org/10.3390/cancers16132301
APA Style
MartÃn GarcÃa-Sancho, A., Presa, M., Pardo, C., MartÃn-Escudero, V., Oyagüez, I., & Ortiz-Maldonado, V.
(2024). Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers, 16(13), 2301.
https://doi.org/10.3390/cancers16132301
